Adults 18 and older living with post-traumatic stress disorder (PTSD) may qualify for a clinical research study evaluating an investigational medication designed to help reduce PTSD symptoms.
Post-Traumatic Stress Disorder (PTSD)
Age Range:
18
Gender:
Male and Female
Location:
West Chester, Pennsylvania
About the Study
This research study is evaluating TSND-201 (methylone), an investigational medication, to determine whether it may help improve symptoms of PTSD. Researchers will compare the study drug to placebo to assess its effectiveness, safety, and tolerability.
Qualifications
You may be able to join if you:
- Are 18 years of age or older.
- Have been diagnosed with PTSD for at least 6 months.
- Have moderate to severe PTSD symptoms.
- Have previously tried at least one PTSD treatment (medication or therapy).
- Are able to attend all study visits and follow study procedures.
- Are willing to stop certain medications that are not allowed during the study, if medically appropriate.
FEATURED STUDIES
General Anxiety Disorder
Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a
COPD
Individuals with chronic obstructive pulmonary disease (COPD) who continue to experience symptoms or flare-ups despite treatment may qualify for a
MDD Study
Adults 18 to 65 years of age with Major Depressive Disorder (MDD) may qualify for a clinical research study evaluating
Chronic Obstructive Pulmonary Disease (COPD)
Adults 40–75 who have COPD and experienced a flare-up in the past year may qualify for a study evaluating an
Post-Traumatic Stress Disorder (PTSD)
Adults 18 and older living with post-traumatic stress disorder (PTSD) may qualify for a clinical research study evaluating an investigational
Bronchiectasis
Individuals with bronchiectasis who experience frequent flare-ups or ongoing respiratory symptoms may qualify for a research study evaluating a home